BPC-157 Where to Buy: $24.50 Is Only Half the Decision

A checklist earns its place only if every line prevents a specific failure. These seven do, and the last column is the one to read first.

The order is not decorative. A supplier failing the first three rows cannot be rescued by the seventh, because a cheap milligram of an unidentified powder is not cheap. One that buries the strength wants judging on vial price, the number that says nothing about the material.

A certificate of analysis reports on one batch, tested on one date, by one laboratory. Read as anything wider it becomes decoration. Three features decide whether it is worth opening.

The batch code has to match the vial in your hand

Character for character, against the code printed on the label. A certificate with no batch code, or one appearing under every product in a catalogue, describes a batch nobody sent you. Ascension Peptides publishes two third-party certificates for its BPC-157 material: Kovera Labs batch 12-05260628 and MZ Biolabs batch 12-01260229. Those are the vendor's own published documents, and their value is that they name a laboratory and a batch a delivery can be checked against. We have not run an assay ourselves.

Purity and identity are different measurements

High-performance liquid chromatography reports how much of the sample sits under the main peak, which is purity. Mass spectrometry reports molecular weight, which is identity, and for BPC-157 the figure to land near is 1419.5 g/mol. Purity alone tells you a powder is 98% one compound without saying which one.

Labelled milligrams are not all peptide milligrams

Part of the mass in a lyophilised vial is counterion, residual solvent and water; acetate and trifluoroacetate salts can carry a tenth of the gross weight. It matters twice, because the labelled figure is the numerator in your concentration and the denominator in your cost per milligram. Our peptide calculator guide covers where the arithmetic assumes a number it cannot verify.

Documents describe the material. This second group decides whether you ever hold it.

Stock location. Domestic stock is the difference between a parcel that leaves the same day and one that crosses a border first. Ascension states same-day dispatch on orders placed before 2pm CST from US stock. A storefront with no cut-off published anywhere, or a three to four week processing note buried in its terms, is very likely ordering your vial after you have paid for it.

Labelling. Research-use wording is not a disclaimer to resent, it is the condition under which the sale is lawful in the United States. A seller advertising healing timelines has stepped outside it and is marketing an unapproved drug, which tells you what to expect from its paperwork.

Recourse. Read the refund terms before checkout and check they cover the failures that actually happen: wrong item, breakage in transit, non-delivery. Keep the outer packaging until the batch code has been matched to the certificate.

Carriage. Free shipping begins at $250. One vial with the code is $24.50, roughly a tenth of the way there, so a single-vial order pays postage, and postage belongs inside your per-milligram figure. Lyophilised powder goes to refrigeration on arrival; our peptide storage guide covers what transit damage looks like.

Most pages answering this query still say BPC-157 is FDA Category 2 and barred from compounding. That was true, and stopped being true in April 2026. The sequence, with dates:

• Never approved. No FDA, EMA or MHRA authorisation for any indication, and no USP or NF monograph.
• September 2023. FDA placed BPC-157 in Category 2, bulk substances that may present significant safety risks. Almost every competing page stops here.
• April 2026. FDA removed it from Category 2 after the nominations were withdrawn, returning it for further evaluation. Removal is not promotion to Category 1.
• 23 to 24 July 2026. The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157 for the 503A Bulks List. That recommendation is advisory and non-binding.
• Today. It is not listed in 21 CFR 216.23 and FDA has issued no final determination.

Net position: unapproved, no longer in Category 2, recommended but not listed. No pharmacist can dispense a substance with no approved product and no listing behind it, which is why the criteria above contain no pharmacy row. The committee's own page is the primary record for what happens next, and our sibling guide on BPC-157 without prescription works through what a research-use sale legally is.

Vial price describes a transaction. Price per milligram describes material. Two listings carry BPC-157 and only one is BPC-157 alone, so the comparison has to name the second compound.

The $2.25 figure is real and it is not cheaper BPC-157. It is a blend price divided by the blend's total mass. If you want TB-500 in the same vial, the stack is the better arithmetic. If you want BPC-157 alone, the honest number is $45.00 divided by the 10 mg of BPC-157 in there, which is $4.50 per BPC-157 milligram.

Quantity tiers, calculated on list

Multiples take 3% off at three vials, 5% at five and 10% at ten, applied to the $49.00 list: $47.53, $46.55 and $44.10 per vial, which is $4.75, $4.66 and $4.41 per mg. All three sit above a single discounted vial at $2.45 per mg. The vendor does not document the tiers combining with the code, so treat them as separate routes and let the cart total settle it.

Per draw, once it is in solution

A 10 mg vial holds 10,000 mcg. Add 2 mL of bacteriostatic water and the solution is 5 mg/mL, which puts 200 units of a U-100 syringe in the vial and makes 0.1 mL, or 10 units, equal to 500 mcg. At $24.50 that is $0.1225 per unit and $1.225 per 500 mcg draw. Fill the same vial with 1 mL instead and it is 10 mg/mL, 100 units total, and 10 units holds 1 mg. Our reconstitution guide, the syringe measurement guide and the reconstitution calculator handle the general case. This is laboratory handling arithmetic, not a schedule for anyone to follow.

The same list applied to the supplier this page recommends, stated plainly enough to argue with.

Two omissions are deliberate. No purity percentage, because that number belongs to the certificate for your batch rather than to a page written months earlier. And no named rival's price, because any competitor figure written here is stale within weeks. For the full cost breakdown see BPC-157 price; for the scoring behind the recommendation, best BPC-157 source.

Criteria bound uncertainty. They do not remove it, and three limits belong in the open.

• A certificate covers a batch, not your vial. A laboratory tests a sample. Between that sample and the vial in your fridge sit filling, capping, storage and transit, none of which the certificate observed.
• The evidence base does not improve with the supplier. The published work is overwhelmingly rodent and cell work, much of it from the same Zagreb group, and the one Phase 2 trial recruiting in 2026 has published no results. Two certificates make a vial verifiable, not effective.
• Tested athletes have a separate problem. WADA prohibits BPC-157 at all times under S0, the class for substances with no current human therapeutic approval. A research-use label makes no difference to a sample.

Weighing BPC-157 against another research peptide, the arithmetic runs the same way but the evidence does not: MOTS-c where to buy covers a mitochondrial peptide at a different price per milligram, retatrutide where to buy a compound with Phase 3 data behind it, and the BPC-157 reference page holds the concentration tables.